

Matteo Tebaldi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3738981/publications.pdf>

Version: 2024-02-01

81
papers

4,895
citations

159525

30
h-index

95218

68
g-index

82
all docs

82
docs citations

82
times ranked

4821
citing authors

#	ARTICLE	IF	CITATIONS
1	Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. <i>Circulation</i> , 2012, 125, 2015-2026.	1.6	640
2	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1482-1490.	6.3	412
3	Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2024-2035.	1.1	394
4	Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2474-2483.	1.2	315
5	Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. <i>Journal of the American College of Cardiology</i> , 2015, 65, 805-815.	1.2	248
6	Diagnostic Performance of In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	240
7	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet</i> , The, 2018, 392, 835-848.	6.3	215
8	Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 268-277.	1.1	162
9	Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 426-436.	1.1	135
10	Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Coroner Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 20-28.	1.1	124
11	Transradial Coronary Catheterization and Intervention Across the Whole Spectrum of Allen Test Results. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1833-1841.	1.2	123
12	Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). <i>European Heart Journal</i> , 2013, 34, 909-919.	1.0	108
13	Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2010, 31, 35-49.	1.0	103
14	Prognostic Value of QFR Measured Immediately After Successful Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2079-2088.	1.1	103
15	Evolving Routine Standards in Invasive Hemodynamic Assessment of Coronary Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1482-1491.	1.1	85
16	Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1132-1137.	1.2	82
17	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006023.	1.4	80
18	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2020, 142, 441-454.	1.6	67

#	ARTICLE	IF	CITATIONS
19	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2010, 160, 804-811.	1.2	66
20	Radiation Exposure and Vascular Access in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2530-2537.	1.2	61
21	Complete revascularization reduces cardiovascular death in patients with ST-segment elevation myocardial infarction and multivessel disease: systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2020, 41, 4103-4110.	1.0	59
22	Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2014, 63, 506-512.	1.2	58
23	Poor response to clopidogrel: current and future options for its management. <i>Journal of Thrombosis and Thrombolysis</i> , 2010, 30, 319-331.	1.0	53
24	Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. <i>European Heart Journal</i> , 2014, 35, 2524-2529.	1.0	49
25	The Assessment of Scales of Frailty and Physical Performance Improves Prediction of Major Adverse Cardiac Events in Older Adults with Acute Coronary Syndrome. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1113-1119.	1.7	49
26	Genetic determinants of on-clopidogrel high platelet reactivity. <i>Platelets</i> , 2011, 22, 399-407.	1.1	48
27	Novel Indices of Coronary Physiology. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008487.	1.4	44
28	Fractional Flow Reserve Evaluation and Chronic Kidney Disease: Analysis From a Multicenter Italian Registry (the FREAK Study). <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 555-562.	0.7	40
29	The 5-Year Clinical Outcomes After a Randomized Comparison of Sirolimus-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1900-1901.	1.2	38
30	Angio-Based Index of Microcirculatory Resistance for the Assessment of the Coronary Resistance: A Proof of Concept Study. <i>Journal of Interventional Cardiology</i> , 2020, 2020, 1-4.	0.5	36
31	Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry. <i>Platelets</i> , 2016, 27, 484-487.	1.1	32
32	10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1165-1178.	1.2	32
33	Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, F19-27.	0.7	30
34	Platelet aggregation values in patients with cardiovascular risk factors are reduced by verbascoside treatment. A randomized study. <i>Pharmacological Research</i> , 2015, 97, 1-6.	3.1	30
35	A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). <i>EuroIntervention</i> , 2016, 12, 1223-1230.	1.4	29
36	On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention: Table 1. <i>Thorax</i> , 2014, 69, 80-81.	2.7	28

#	ARTICLE	IF	CITATIONS
37	Physiology-guided revascularization versus optimal medical therapy of nonculprit lesions in elderly patients with myocardial infarction: Rationale and design of the FIRE trial. <i>American Heart Journal</i> , 2020, 229, 100-109.	1.2	24
38	Coronary Microvascular Dysfunction: PET, CMR and CT Assessment. <i>Journal of Clinical Medicine</i> , 2021, 10, 1848.	1.0	24
39	Thrombin generation assay. <i>Blood Coagulation and Fibrinolysis</i> , 2012, 23, 680-687.	0.5	22
40	Coagulation Factors and Recurrence of Ischemic and Bleeding Adverse Events in Patients with Acute Coronary Syndromes. <i>Thrombosis Research</i> , 2013, 132, 151-157.	0.8	22
41	Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. <i>EuroIntervention</i> , 2017, 13, 78-86.	1.4	21
42	Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 192-194.	1.9	19
43	Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain DES Candidates study. <i>American Heart Journal</i> , 2013, 166, 831-838.	1.2	18
44	Safety and Feasibility of Transradial Mini-Invasive Balloon Aortic Valvuloplasty. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1375-1377.	1.1	18
45	Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX " Radiation Dose study (RAD-MATRIX). <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 209-213.	0.3	17
46	Comparison of quantitative flow ratio, Pd/Pa and diastolic hyperemia-free ratio versus fractional flow reserve in non-culprit lesion of patients with non-ST-segment elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1057-1065.	0.7	17
47	Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1824-1826.	1.9	15
48	Bioresorbable vascular scaffold overlap evaluation with optical coherence tomography after implantation with or without enhanced stent visualization system (WOLFIE study): a two-centre prospective comparison. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 211-223.	0.7	15
49	Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 32-40.	1.8	15
50	Usefulness of Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina Pectoris. <i>American Journal of Cardiology</i> , 2021, 139, 22-27.	0.7	15
51	Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 1903-1911.	1.9	14
52	Seven french radial artery access for PCI: A prospective single-center experience. <i>International Journal of Cardiology</i> , 2014, 176, 1074-1075.	0.8	14
53	Fractional flow reserve implementation in daily clinical practice: A European survey. <i>International Journal of Cardiology</i> , 2016, 207, 206-207.	0.8	14
54	Safety, efficacy and impact on frailty of mini-invasive radial balloon aortic valvuloplasty. <i>Heart</i> , 2021, 107, 874-880.	1.2	13

#	ARTICLE	IF	CITATIONS
55	Enhanced stent visualization systems during PCI: A case series and review of literature. <i>Journal of Cardiology Cases</i> , 2015, 12, 1-5.	0.2	12
56	Safety and efficacy of coronary sinus narrowing in chronic refractory angina: Insights from the RESOURCE study. <i>International Journal of Cardiology</i> , 2021, 337, 29-37.	0.8	12
57	A counseling program on nuisance bleeding improves quality of life in patients on dual antiplatelet therapy: A randomized controlled trial. <i>PLoS ONE</i> , 2017, 12, e0182124.	1.1	12
58	Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 523-532.	1.3	11
59	Angiography-derived versus invasively-determined index of microcirculatory resistance in the assessment of coronary microcirculation: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 2018-2025.	0.7	11
60	Impact of a recent hospitalization on treatment and prognosis of ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 167, 296-297.	0.8	10
61	Abciximab: a reappraisal of its use in coronary care. <i>Biologics: Targets and Therapy</i> , 2008, 2, 29.	3.0	8
62	Contrast Associated Acute Kidney Injury and Mortality in Older Adults with Acute Coronary Syndrome: A Pooled Analysis of the FRASER and HULK Studies. <i>Journal of Clinical Medicine</i> , 2021, 10, 2151.	1.0	8
63	Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study. <i>American Heart Journal</i> , 2018, 196, 113-118.	1.2	7
64	Adenosine-Free Indexes vs. Fractional Flow Reserve for Functional Assessment of Coronary Stenoses: Systematic Review and Meta-Analysis. <i>International Journal of Cardiology</i> , 2020, 299, 93-99.	0.8	7
65	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: a Multicenter Randomized Open-label Trial in Patients with ST-elevation Myocardial Infarction Referred for Primary Percutaneous Intervention (FABOLUS FASTER) Trial: Design and Rationale. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 110-119.	1.1	7
66	Prospective Identification of Stent Fracture by Enhanced Stent Visualization System During Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2017, 81, 82-89.	0.7	7
67	Safety evaluation of tirofiban. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 801-819.	1.0	6
68	Comparison of Verapamil versus Heparin as Adjunctive Treatment for Transradial Coronary Procedures: The VERMUT Study. <i>Cardiology</i> , 2018, 140, 74-82.	0.6	6
69	Fractional flow reserve: Current applications and overview of the available data. <i>World Journal of Clinical Cases</i> , 2015, 3, 678.	0.3	6
70	Acetylcholine Use in Modern Cardiac Catheterization Laboratories: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 1129.	1.0	6
71	Medical and interventional management of patients with severe thrombocytopenia undergoing percutaneous coronary intervention. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 153-156.	1.9	5
72	Quantitative flow ratio as a new tool for angiography-based physiological evaluation of coronary artery disease: a review. <i>Future Cardiology</i> , 2021, 17, 1435-1452.	0.5	4

#	ARTICLE	IF	CITATIONS
73	Complete versus culprit-only strategy in older MI patients with multivessel disease. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 970-978.	0.7	4
74	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. <i>International Journal of Cardiology</i> , 2019, 277, 60-65.	0.8	2
75	Index of microcirculatory resistance assessment in patients with new diagnosis of left ventricular dilatation without significant coronary artery lesions: IMPAIRED pilot trial. <i>European Journal of Heart Failure</i> , 2020, 22, 561-563.	2.9	2
76	One-Year Clinical Outcomes of Forty-Eight Millimeter Everolimus-Eluting Stent Implanted in Very Long Lesions: A Propensity-Matched Comparison (The FREIUS Study). <i>Journal of Invasive Cardiology</i> , 2018, 30, 133-137.	0.4	2
77	Shedding Light on Treatment Options for Coronary Vasomotor Disorders: A Systematic Review. <i>Cardiovascular Drugs and Therapy</i> , 2024, 38, 151-161.	1.3	2
78	The impact of periprocedural myocardial infarction on mortality in older adults with non-ST-segment elevation acute coronary syndrome. <i>Journal of Cardiovascular Medicine</i> , 2021, Publish Ahead of Print, 546-552.	0.6	1
79	The unbearable lightness of the instantaneous wave-free ratio/fractional flow reserve discordance. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 116-118.	0.6	1
80	Low FFR equal to low ischemia: Really?. <i>International Journal of Cardiology</i> , 2018, 265, 81.	0.8	0
81	The management of patients with acute myocardial infarction: route to tailored therapy. <i>International Journal of Cardiology</i> , 2021, 343, 1-2.	0.8	0